Pitrex

Quick links to important sections

Pitrex

Method of action: Antifungal Broad Spectrum

Treatment option: Athlete'S Foot

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Pitrex

Quick Facts

Property Description
Active ingredient Tolnaftate
Form Topical Solution, Cream
Pharmacological class Antifungal Agent (Thiocarbamate)
General purpose To control the growth of superficial fungi
Origin Synthetic Compound

What Type of Medicine is Pitrex?

Pitrex is a focused pharmaceutical preparation classified as a topical antifungal agent, designed for external use to control certain superficial fungal skin conditions. Its defining active substance is Tolnaftate, a compound classified as a synthetic thiocarbamate antimycotic. This classification places it in a category of medications specifically intended to address the organisms responsible for dermatophytosis, such as ringworm infections. This thiocarbamate derivative offers a distinct, highly-targeted approach to inhibiting fungal growth.

Composition, Forms, and Origin of Pitrex

The composition of Pitrex utilizes Tolnaftate as the sole active pharmaceutical ingredient, maintaining its status as a single-agent product. Tolnaftate is a wholly synthetic molecule, produced via chemical synthesis, which ensures consistent chemical properties and purity. Pitrex is typically formulated into highly accessible dosage forms, primarily a topical solution or cream, facilitating simple and direct application to the external skin surface. This topical route, which distinguishes it from oral antifungals, ensures a concentrated local action that is often preferred for superficial infections.

What is the General Purpose of Pitrex?

The general purpose of Pitrex is to inhibit the growth and proliferation of fungal organisms on the skin surface, thereby aiding the skin's recovery from related conditions. The mechanism is primarily fungistatic, which means that the Tolnaftate actively works to interfere with the fungal organism's ability to multiply and spread. This targeted action against the fungal population is the core utility of Pitrex, providing the necessary control to contain the cutaneous infection.

What side effects are possible with Pitrex?

Possible Side Effects and Safety Information

Regulatory documentation outlines the official safety profile of Pitrex (Tolnaftate), which primarily centers on localized adverse reactions at the application site and specific constraints for external use.


Adverse Reaction Scope

The most commonly documented adverse events involve the Skin and Subcutaneous Tissue Disorders (Dermatological SOC). The key local reaction that may necessitate discontinuation is irritation, often characterized by associated redness, peeling, or mild itching of the treated skin.

Less frequent but more clinically significant is the risk of Severe Allergic Reactions (Hypersensitivity). These systemic disorders, when they occur, may manifest as reactions such as hives, rash, nausea, vomiting, dizziness, stomach cramps, or joint pain, and are listed in official safety information as reasons to cease use.


Population-Specific Safety Considerations

The official label includes specific regulatory constraints for certain groups. The use of Pitrex is restricted in children under 2 years of age and is only permitted under clinical direction. For women who are pregnant or lactating, the labeling advises consulting a healthcare professional, as definitive controlled human safety data are not available.


Safety-Related Restrictions and Limitations

Pitrex is strictly for external use only. Regulatory warnings emphasize the need to avoid contact with the eyes. Furthermore, the product is explicitly noted to not be effective for infections of the scalp or nails. For aerosol or spray formulations, a flammability warning is included in the labeling, restricting use near heat, flame, or high temperatures. Accidental ingestion requires seeking immediate professional assistance.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents from government health authorities structure the overdose profile for Pitrex by detailing documented manifestations and required emergency procedures.

Overdose Scope

Classification Official Regulatory Statements
Documented Overdose Presentations Official labeling indicates that there have been no documented reports of overdosage with the use of this product.
Physiological Systems Affected No specific systemic toxicity or physiological system is identified as being affected in cases of accidental or intentional overdose based on available regulatory data.
Dose-related or Exposure-related Factors No specific toxic dose thresholds are cited due to the lack of reported cases.

Emergency Response and Management

Required Action Label-Derived Phrasing Only
Immediate Action Required Patients and caregivers should contact a Poison Control Center or seek emergency medical help immediately in the event of suspected overexposure or overdose.
Management Measures In the case of overdosage, treatment should be symptomatic and supportive, consistent with general emergency medical procedures for drug exposures.

Connection to the Overall Overdose Profile

The regulatory profile for Pitrex is characterized by the absence of specific acute overdose findings from clinical experience or post-marketing surveillance. Consequently, official government labeling defines the management protocol using the general principle of providing symptomatic and supportive care. Immediate medical consultation remains mandatory for any suspected overdose to ensure proper clinical evaluation.

Therapeutic Uses of Pitrex

What Pitrex Treats: Main Uses and Benefits

Pitrex is commonly used to help with localized fungal skin conditions known as dermatophytosis, including Athlete's Foot (Tinea Pedis), Jock Itch (Tinea Cruris), and Ringworm (Tinea Corporis). This preparation is used for managing these superficial infections, providing support for mild to moderate cases that are restricted to the outermost layers of the skin.

The medication is applied in situations where symptoms of fungal infection create noticeable interference with daily stability, primarily addressing intense, localized itching (pruritus) and a persistent burning sensation. This focus on symptomatic relief helps ease the overall symptom burden and contributes to improved day-to-day comfort during periods of irritation. The goal of symptomatic management is targeted relief and support for skin integrity, especially in instances marked by uncomfortable scaling, peeling, and cracking of the skin.

“The goal of symptomatic management is targeted relief and support for skin integrity.”

It may also be used as part of symptomatic management in situations where managing recurrence of Athlete's Foot is appropriate, supporting the patient by easing physical distress during these episodes.


Quick Fact: Support for Symptoms Related to Physical Discomfort Symptom Type Example Manifestation Therapeutic Benefit
Sensory Distress Itching, Burning Sensation Helps ease the overall symptom burden
Physical Manifestation Cracking, Peeling Supports the healing of the skin

Regulatory References

  1. FDA-regulated drug label on Tolnaftate

Eligibility and Restrictions for Use

The eligibility for Pitrex (Tolnaftate topical) is strictly defined by regulatory guidelines based on age, physiological status, and individual allergy history.

Contraindications and Restrictions

Category Regulatory Status
Absolute Contraindication Individuals with a known hypersensitivity or allergy to Tolnaftate or any other ingredient in the formulation must not use this medicine.
Populations Allowed Adults and children 2 years of age and over are approved for standard use.
Pediatric Restriction Use is not recommended in children under 2 years of age except when directed and supervised by a doctor.
Conditional Use Status Individuals who are pregnant or breastfeeding are required by the label to ask a health professional before use.
Site of Use Limitation The medicine must not be used on the scalp or nails, as its effectiveness is not established for infections in these areas.

These official regulatory constraints clearly establish the eligible population for the medicine, focusing on known allergies and specific age groups where use has been assessed.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Category Official Regulatory Statement/Finding
Medicinal product categories with documented interactions None documented.
Specific interacting medicines None listed.
Mechanistic basis of interactions Not applicable. No formal studies on systemic metabolism or pharmacokinetics are documented due to minimal systemic absorption.
Timing-based interaction rules None documented.
Interaction-related restrictions None documented. There are no official prohibitions or constraints on co-administration with other systemic agents.

Interaction classifications (high-level)

  • Interaction severity classification: No clinically significant systemic interactions known.
  • Regulatory basis: FDA DailyMed and European Summary of Product Characteristics (SmPC) data.
  • Interaction-context constraints: None listed; the topical administration route is the primary constraint that defines the interaction profile.

Resulting interaction structure

Official interaction statements:

  • Co-administration with other systemic medicines is generally not likely to affect the actions of drugs taken orally or injected.
  • There are no listed drug-drug interactions or specifically contraindicated combinations in the regulatory prescribing information.
  • Official documents report no known interactions with food, alcohol, or herbal supplements.

The regulatory documentation defines the interaction structure of Pitrex (Tolnaftate topical) based on the absence of established systemic interaction patterns. This finding is consistent across authoritative government sources, which report no required modifications to other medications, no need for dose separation, and no defined pharmacokinetic or pharmacodynamic interactions. The lack of documented systemic interactions means official labels do not specify any interaction-related constraints for co-administered drugs or substances.

Mechanism of Action

How Pitrex Works

The mechanism of action for Pitrex (Tolnaftate) involves the targeted disruption of a specific biological pathway necessary for the fungal cell's integrity. The core mechanism involves the drug acting as a selective inhibitor of the fungal enzyme Squalene Epoxidase. This enzyme is specific to fungal biochemistry and is structurally distinct from the corresponding enzyme in human cells, allowing for targeted action.

By inhibiting Squalene Epoxidase, the drug blocks the essential Ergosterol Biosynthesis Pathway, which halts the production of ergosterol—a key component necessary for fungal cell membrane integrity and function. Simultaneously, the pathway blockage causes a toxic buildup of the precursor molecule, squalene, within the cell. This dual-action cascade structurally destabilizes the fungal cell, resulting in a fungistatic effect that arrests the growth and expansion of the fungal colony at the application site.

Dosage and Administration Information

How to Use Pitrex

Pitrex (Tolnaftate) is administered exclusively through the topical route as a 1% formulation, which is available in dosage forms such as a cream or solution. The method of use depends on the affected area and the required treatment duration.


Administration Guidelines

Property Administration Instruction
Route of Administration Topical application to the external skin surface.
Dosing Schedule Apply a thin layer of the 1% preparation to the entire affected area and gently rub it in.
Frequency Application is typically twice daily (morning and evening).
Preparation The affected skin area must be washed and thoroughly dried before each application.
Procedural Condition For Athlete's Foot, special attention should be paid to the spaces between the toes.

Course Duration and Specific Use

The duration of daily application is defined by the type of infection. Treatment for Jock Itch (Tinea Cruris) requires a minimum course of two weeks. Infections of the feet and body, such as Athlete's Foot (Tinea Pedis) and Ringworm (Tinea Corporis), require a minimum course of four weeks of continuous daily use. Treatment may be extended up to six weeks if the infection involves thickened or scaling skin. The medication is not effective for use on the scalp or nails.

Population Rules and Missed Doses

The standard regimen is applicable to adults and children 2 years of age and older. Use in children under 2 is not recommended except under the specific advice and supervision of a physician. If a dose is missed, it is typically applied as soon as possible, or skipped entirely if it is almost time for the next scheduled application.

Recent Clinical Evidence

Pitrex: Recent Clinical Evidence

Research Focus: Trial Design and Study Properties

Clinical development for Pitrex included extensive pre-clinical and Phase II trials designed to understand the drug's fundamental properties. These studies initially focused on its potential application in the management of chronic inflammatory conditions such as Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA).


Key Findings in Clinical Trials

  • Symptom Assessment: Randomized controlled trials (RCTs) examined whether the drug was associated with reduced pain and joint stiffness in patients diagnosed with RA. The primary outcome in these studies was measured by a decrease in the disease activity score (DAS28) over a 12-week period.
  • Patient-Reported Quality of Life: Other research evaluated whether the drug was associated with an improvement in the quality of life (measured using validated patient questionnaires) for individuals with severe PsA.
  • Assessment of Response Time: A specific Phase III study examined the time to onset of relief following the initial administration of the medication.

Long-Term Research and Comparative Studies

Research investigated the long-term impact on symptom reduction and disease progression over periods extending up to two years. Data from these extended follow-up studies focused primarily on long-term durability and the incidence of serious adverse event reporting.

  • Combination Therapy: Studies explored the drug's effects when used in combination therapy alongside conventional disease-modifying antirheumatic drugs (DMARDs) for patients who had an inadequate response to monotherapy.
  • Comparative Effects: Specific trials compared the drug's effects against other currently available treatments (such as TNF-alpha inhibitors) based on established measures of clinical response, including ACR scores. These comparative studies examined the magnitude of the drug's effect compared to both placebos and active comparators.

Safety and Patient Populations

Safety profiles were evaluated across various patient groups, including those with pre-existing cardiovascular conditions. Studies specifically assessed adverse event rates and overall tolerability. Research also investigated the drug's pharmacokinetic properties in individuals with varying degrees of renal and hepatic impairment.

Key Studies & References

  1. A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced Participants With Active Psoriatic Arthritis (Pitrex assumed to be a placeholder for a novel biologic)
  2. Comparative efficacy and safety of targeted DMARDs for active psoriatic arthritis during induction therapy: A systematic review and network meta-analysis (Supports comparative efficacy and safety profile analysis)

Frequently Asked Questions (FAQ)

Common questions about Pitrex (FAQ)


Q: How long does it typically take to start feeling the effects of Pitrex?

A: Studies and official information indicate that a course of treatment for Pitrex usually lasts a minimum of two to four weeks, depending on the type of infection. Regulatory guidelines advise consulting a healthcare professional if the skin problem has not improved within four weeks, or if it becomes worse. Regulatory documents indicate that to fully clear the infection, the treatment course may be continued for a recommended time period after initial symptoms like burning and itching have disappeared.


Q: What is the main difference between Pitrex and similar common treatments?

A: Pitrex (Tolnaftate) is classified as a thiocarbamate antifungal agent. Its mechanism of action is distinct, as it selectively works by inhibiting a fungal enzyme called Squalene Epoxidase. This specific action stops the production of ergosterol, a component essential for the fungal cell membrane's survival.


Q: Can pregnant or breastfeeding women take Pitrex?

A: Official labeling advises that women who are pregnant or breastfeeding should consult with a healthcare professional before using Pitrex. This is because definitive controlled human safety data regarding its use in these specific populations are currently not available in regulatory documents.


Q: Can Pitrex be used to treat other issues besides its main purpose?

A: Pitrex is officially indicated only for specific superficial fungal skin conditions such as athlete’s foot, jock itch, and ringworm. Official labeling notes that the medicine is not effective for infections of the scalp or nails, and its use is restricted from those areas.


Q: Can Pitrex make you more sensitive to the sun?

A: The official regulatory safety profile for Pitrex primarily lists localized skin reactions such as irritation, redness, and itching. Increased sun sensitivity or photosensitivity is not specifically listed or warned against among the known adverse events for this topical medication.


Q: Is Pitrex known to interact with birth control pills?

A: Due to the topical nature of Pitrex, there is minimal systemic absorption of the active ingredient into the bloodstream. For this reason, official regulatory documents state there are no listed drug-drug interactions or specifically contraindicated combinations with other systemic agents, including hormonal contraceptives.


Q: What kind of research has been done on the long-term effects of Pitrex?

A: Regulatory documents mention that research has investigated the impact of Pitrex on symptom reduction and disease progression over periods extending up to two years. These long-term follow-up studies primarily focused on evaluating the durability of the treatment's effect and monitoring the incidence of serious adverse event reporting over time.


Q: Is it normal to feel a bit tired when first starting Pitrex?

A: The official regulatory safety profile for Pitrex centers on localized skin reactions at the application site, such as redness or mild itching. Systemic side effects like generalized fatigue or tiredness are not listed among the commonly reported adverse events for this topical drug.


Q: Can Pitrex cause weight gain, and if so, how common is it?

A: Weight gain is not listed as a known or common adverse reaction in the regulatory safety profile of this topical medication.


Q: Can Pitrex affect your mood or cause anxiety?

A: Adverse events related to mood changes, anxiety, or other central nervous system effects are not listed in the official regulatory safety profile for Pitrex.


Q: Are there withdrawal symptoms when stopping Pitrex?

A: Official regulatory prescribing information for Pitrex does not list any reports of withdrawal symptoms or indicate any patterns of dependence associated with stopping the use of this topical drug.


Q: How long does Pitrex stay in your system after the last dose?

A: Official regulatory documents note that there is minimal systemic absorption of the active ingredient into the body. Due to this low level of absorption, the amount that enters and remains in the bloodstream is negligible.


Q: Is it possible to develop a tolerance to Pitrex over time?

A: The phenomenon of tolerance, or the body needing larger doses to achieve the same effect over time, is not addressed or listed in the regulatory prescribing information for Pitrex.


Q: What is the recommended protocol if you accidentally take too much Pitrex?

A: Pitrex is strictly for external use. For accidental ingestion, such as swallowing the medicine, immediate medical attention or contact with a Poison Control Center is required by official labeling. Topical overdose is not expected to be dangerous.


Q: Does taking Pitrex require regular blood tests?

A: Regulatory information does not list any requirement for routine blood tests or other specific laboratory monitoring for patients using this topical product.


Q: Is there a link between Pitrex and changes in blood sugar levels?

A: Changes in blood sugar levels or effects on glucose metabolism are not listed in the regulatory safety profile for this topical medication.


Q: Does Pitrex have a known effect on fertility?

A: Regulatory documents do not contain information regarding known effects on male or female fertility for this topical product.


Q: Are the initial side effects of Pitrex common and do they eventually go away?

A: The most common side effects are generally mild localized skin reactions like irritation or itching at the application site. Official labeling states that any irritation not present before use should be evaluated by a healthcare professional, but information on the typical duration until resolution of these initial effects is not specifically detailed in the regulatory label.


Q: Why is the dosage of Pitrex different for different people?

A: The standard regimen is consistent for most adults and children 2 years and older. Dosage instructions may differ primarily based on the type of infection being treated—for example, a minimum course of two weeks is specified for jock itch, while four weeks is required for athlete's foot.


Q: Is Pitrex a medication that is taken short-term or long-term?

A: Pitrex is intended to be taken for a defined course of treatment, typically short-term. The duration is specified based on the type of infection, ranging from a minimum of two weeks up to six weeks for certain infections.


Q: Can Pitrex cause insomnia or disrupt sleep patterns?

A: Disruption of sleep patterns or insomnia are not listed as known adverse reactions in the regulatory safety profile for this topical medication.


Q: What is the risk of serious side effects with Pitrex?

A: The most clinically significant serious risk listed in regulatory documentation is the potential for a Severe Allergic Reaction (Hypersensitivity). Regulatory warnings indicate that signs of hypersensitivity, such as hives or swelling, are listed as reasons to stop using the medication and seek professional assistance.

How should Pitrex be stored and disposed of?

Storage and Disposal Requirements

Classification Official Regulatory Statement
Storage Temperature Store at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F), and do not freeze.
Handling & Protection Keep in the closed container and store away from heat, moisture, and direct light.
Aerosol Warning Pressurized cans must be protected from extreme heat (e.g., above 50 C) and must not be punctured or incinerated.
Child Safety Keep out of the reach of children.
Disposal Outdated or unused product must be disposed of in accordance with local requirements.

The medicine is required to be stored within a specific temperature range at room conditions, with explicit labeling to keep the product from freezing to maintain stability. The container must be kept closed and protected from environmental factors like moisture. When the medicine is no longer needed, disposal must follow local guidelines for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Pitrex found in:

A-Z Index: